Rare disease drug pricing and access: corporate profit motives, regulatory gaps, and global health inequities shape Neurocrine's risk‑benefit debate
Original framing: “STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk” — STAT News
Marginalised voices—including low‑income families, racial minorities, and patient advocates without corporate backing—are rarely quoted in mainstream coverage, yet they experience the greatest barriers to access and the highest burden of adverse outcomes. Amplifying these perspectives is crucial for equitable policy formulation.
Neurocrine's Prader‑Willi therapy sits at the intersection of profit‑driven biotech incentives, regulatory shortcuts, and global health inequities, a confluence that mainstream headlines reduce to a simple risk‑benefit equation.
Historical misuse of orphan‑drug policies, coupled with the absence of Indigenous and marginalised perspectives, reveals a structural bias that privileges corporate earnings over equitable care. Cross‑cultural evidence shows that community‑based support can mitigate drug risks, while scientific gaps demand robust post‑market surveillance and outcome‑linked pricing. By enacting tiered pricing, data trusts, integrated care models, and outcome‑based incentives, stakeholders—from regulators to patient coalitions—can transform the current paradigm into one that delivers genuine benefit across diverse populations.